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Abstract: 
Dipeptidyl peptidase 4 (DPP4) is an exopeptidase found either on cell surfaces where it is highly 
regulated in terms of its expression and surface availability (CD26) or in a free/circulating soluble 
constitutively available and intrinsically active form. It is responsible for proteolytic cleavage of many 
peptide substrates. In this review we discuss the idea that DPP4-cleaved peptides are not necessarily 
inactivated, but rather can possess either a modified receptor selectivity, modified bioactivity, new 
antagonistic activity, or even a novel activity relative to the intact parent ligand.  
We examine in detail five different major DPP4 substrates: glucagon-like peptide 1 (GLP-1), glucose-
dependent insulinotropic polypeptide (GIP), peptide tyrosine-tyrosine (PYY), and neuropeptide Y (NPY), 
and stromal derived factor 1 (SDF-1 aka CXCL12). We note that discussion of the cleaved forms of these 
five peptides are underrepresented in the research literature, and are both poorly investigated and 
poorly understood, representing a serious research literature gap. We believe they are understudied 
and misinterpreted as inactive due to several factors. This includes lack of accurate and specific 
quantification methods, sample collection techniques that are inherently inaccurate and inappropriate, 
and a general perception that DPP4 cleavage inactivates its ligand substrates. 
Increasing evidence points towards many DPP4-cleaved ligands having their own bioactivity. For 
example, GLP-1 can work through a different receptor than GLP-1R, DPP4-cleaved GIP can function as a 
GIP receptor antagonist at high doses, and DPP4-cleaved PYY, NPY, and CXCL12 can have different 
receptor selectivity, or can bind novel, previously unrecognized receptors to their intact ligands, 
resulting in altered signaling and functionality. We believe that more rigorous research in this area could 
lead to a better understanding of DPP4’s role and the biological importance of the generation of novel 
cryptic ligands. This will also significantly impact our understanding of the clinical effects and side effects 
of DPP4-inhibitors as a class of anti-diabetic drugs that potentially have an expanding clinical relevance. 
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This will be specifically relevant in targeting DPP4 substrate ligands involved in a variety of other major 
clinical acute and chronic injury/disease areas including inflammation, immunology, cardiology, stroke, 
musculoskeletal disease and injury, as well as cancer biology and tissue maintenance in aging. 
 
Keywords: 
Dipeptidyl peptidase 4, glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide, peptide 
tyrosine-tyrosine, neuropeptide Y, CXCL12. 
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Abbreviations: 
Abbreviation Phrase 
ACKR3 Atypical chemokine receptor 3 
ADA Adenosine deaminase 
ASCs Adipose stem cells 
BMSCs Bone marrow mesenchymal stem cells 
CD26 Cluster of differentiation 26 
CXCR4 C-X-C chemokine receptor type 4 
DPP4 Dipeptidyl peptidase 4 
ECM Extracellular matrix 
F344 Fischer 344 rats 
GAGs Glycosaminoglycans 
G-CSF Granulocyte-colony stimulating factor 
GIP Glucose-dependent insulinotropic polypeptide 
GIP-R Glucose-dependent insulinotropic polypeptide receptor 
GIT Gastrointestinal tract 
GLP-1 Glucagon-like peptide 1 
GLP-1R Glucagon-like peptide 1 receptor 
GPCR G-protein coupled receptor 
HIF-1 Hypoxia-inducible factor 
HNF Hepatocyte nuclear factor 
HSPCs Hematopoietic stem and progenitor cells 
HUVECs Human umbilical vein endothelial cells 
MS Mass spectrometry 
NPY Neuropeptide Y 
NSC Neural stem cells 
PYY Peptide tyrosine-tyrosine 
RIC Remote ischemic conditioning 
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sCD26 Soluble cluster of differentiation 26 
SDF-1 Stromal Cell-Derived Factor-1 
SPA Scintillation proximity assays 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
 
Table of Contents: 
Title Page Number 
1. Introduction 7 
2. DPP4 10 
3. GLP-1 20 
4. GIP 25 
5. PYY 29 
6. NPY 33 
7. CXCL12, Stromal Cell-Derived Factor 1 (SDF-1) 36 
References 46 
   
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
 
1. Introduction: 
Dipeptidyl peptidase 4 (DPP4) is a highly conserved exopeptidase found widely on the surface of 
epithelial, endothelial, stromal, stem and immune cells (Mulvihill & Drucker, 2014). In its cell membrane 
associated form it is referred to as cluster of differentiation 26 (CD26). DPP4 is a ubiquitous enzyme that 
is expressed in different compartments, including liver, kidney, gastrointestinal tract (GIT) and bone 
marrow (Ambrosi, et al., 2017; Mentlein, 1999; Ou, et al., 2013). It also has a soluble form (sCD26/DPP4) 
that can be found in the circulation and in various tissue compartments. DPP4 regulates the activity of 
many different chemokines and peptide hormones, and it acts by cleaving off N-terminus dipeptides 
typically with a penultimate alanine or proline, although under some conditions other amino acids may 
be targeted (Broxmeyer, 2013; Drucker, 2007; Mortier, et al., 2016). 
CD26 is found as a single pass transmembrane protein that forms homodimers on most cells and in the 
majority of tissues (Mulvihill & Drucker 2014). Regulation of trans-membrane CD26 activity occurs at 
multiple levels, including control of gene and protein expression, regulation of the transfer of CD26 to 
the cell surface, interaction with binding partners, and modulation of enzyme activity  (Mulvihill & 
Drucker, 2014). Expression of cell surface trans-membrane, as well as intercellular membrane pools of 
trans-membrane CD26, is tightly controlled. Transition of CD26 to  the surface of cells is highly regulated 
and can be initiated rapidly resulting in cell surface levels going from no CD26, or minimal basal levels, to 
very high levels in response to a large number of cell and tissue targeting factors such as interleukines, 
hypoxia-inducible factor 1 (HIF-1), interferons, retinoic acid, hepatocyte nuclear factor (HNF), 
granulocyte-colony stimulating factor (G-CSF), angiotensinogen II, classical leukocyte cellular activation 
(e.g. of T and B Cells), as well as modification of activity by post-translational glycosylation and subunit 
dimerization (Aroor, et al., 2016; Bauvois, et al., 2000; Christopherson, et al., 2003a; Chung, et al., 2010; 
Dang, et al., 2008; De Meester, et al., 1999; Gu, et al., 2008; Klemann, et al., 2016; Metzemaekers, et al., 
2016; Mortier, et al., 2016; Mulvihill & Drucker, 2014; Shin, et al., 2017). Functionally, DPP4 is involved 
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in numerous cellular processes including cell-cell interaction, cell mobilization, cell migration, and 
membrane-associated activation of intracellular signal transduction pathways (De Meester, et al., 1999; 
Lambeir, et al., 2003). CD26 is a relatively large protein consisting of 766 amino acids, most of which are 
extracellular, with a hydrophobic transmembrane anchor from amino acids 7 to 28, and a very short 
intracellular sequence consisting of 6 amino acids (Abbott, et al., 1994). The soluble form of the 
peptidase (sCD26/DPP4), composed of the extracellular amino acids 39-766, is shed into the 
extracellular environment by a number of matrix metalloproteinases (Havre, et al., 2008; Varin, et al., 
2018). Unlike the tightly regulated expression/activity of the transmembrane parent form (CD26) on 
cells and within tissues, the soluble DPP4 (sCD26) is widely present in plasma and other tissue 
compartments and is constitutively fully enzymatically active (Klemann, et al., 2016; Mortier, et al., 
2016).  Indeed endogenous levels of soluble DPP4 may not represent a rate-limiting factor, allowing 
cleavage of most of its substrate pools in those compartments (Carbone, et al., 2017a; Carbone, et al., 
2017b). 
Only a limited number of review and primary experimental papers have highlighted the complex role 
that DPP4 plays in the generation of cryptic substrate ligands and the need to consider how these 
changes to the nature of the truncated substrate’s signaling and functional activity impacts experimental 
data interpretation (Mortier, et al., 2008; Mulvihill & Drucker, 2014; O'Leary, et al., 2013). As a 
consequence, the idea that DPP4 proteolysis leads to partial or total inactivation of its substrates is still 
widely accepted and taken for granted. However,  there is a growing literature that supports the idea 
that DPP4 metabolites can have selective, antagonistic or even novel signaling properties and functions 
(Cheng, et al., 2017b; Janssens, et al., 2017; Kim, et al., 2014; Klemann, et al., 2016; Mentlein, 1999; 
Mulvihill & Drucker, 2014; Ou, et al., 2013; Szpakowska, et al., 2018; Tarantola, et al., 2012; Ziarek, et al., 
2017). We believe that the concept that in many cases DPP4 can alter substrate function, rather than 
just inactivating the ligand’s functionality is still an underrepresented view in the overall scientific 
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literature; one that carries tremendous experimental, interpretative as well as clinical repercussions. In 
this review, we highlight five major DPP4 substrates that are not inactivated, but rather demonstrate 
new, or revealed cryptic, interactions and function. We show that DPP4 can modulate the function of 
the substrate not only by interfering with the substrate’s ability to either bind or activate its receptor, 
but truncation can antagonize the receptor or alter the ratio of binding and activation between primary 
and secondary receptors or lead to interactions with a new receptor by the cleaved substrate that is not 
a target of the intact parent ligand. In many cases, DPP4-truncated peptides have complex novel 
functions that are not adequately appreciated. Excitingly, understanding this unexpected cryptic 
bioactivity is an important new area for research as it is underappreciated and represents a major gap in 
the research literature. The cryptic ligand activities come with significant clinical implications and call for 
new interpretations of some previous research results (Metzemaekers, et al., 2016; Mulvihill & Drucker, 
2014; Ou, et al., 2013).  
This review will focus on DPP4 substrates that have bioactivity upon cleavage by DDP4. We are referring 
to these substrates in the title as cryptic bioactive ligands, which means that they develop a new 
previously hidden, bioactivity after post-translational modification (Brandt, et al., 2006). These 
substrates include glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), 
peptide tyrosine-tyrosine (PYY), neuropeptide Y (NPY), and the cytokine Stromal Cell-Derived Factor-1 
(SDF-1, or CXCL12 in the revised cytokine nomenclature (Zlotnik & Yoshie, 2000)). These five substrates 
can be classified into three main classes: incretin hormones, pancreatic polypeptides, and chemokines. 
Both GLP-1 and GIP are incretin peptides released by gut, and are mainly involved in postprandial 
activation of insulin secretion and clearance of glucose (Drucker, 2003). PYY and NPY are both members 
of the pancreatic polypeptide family, which is involved in regulating a large array of biological functions 
including appetite control, behavioral stress responses, angiogenesis, and blood pressure (Groneberg, et 
al., 2004; Mentlein, 1999). A subset of chemokines and cytokines are starting to be recognized as DPP4 
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targets that may have biological functions following cleavage (Broxmeyer, et al., 2016; Metzemaekers, 
et al., 2016; Ou, et al., 2013; Vanheule, et al., 2018). CXCL12 is the best studied of these. CXCL12 is a 
chemokine/cytokine involved in regulation of cell mobilization, migration and homing during tissue 
development, tissue maintenance and disease for numerous cell types, as well as being involved in the 
regulation of complex processes such as angiogenesis, hematopoiesis, and tissue repair (Brandt, et al., 
2006; Bromage, et al., 2014). While we have selected these five specifically due to their relatively 
accepted and maturing presence in the literature - they are not the only examples of DPP4 substrates 
with cryptic bioactivity. Additionally, not all DPP4 substrate metabolites will likely have cryptic 
bioactivity.  We will introduce each one of these five substrates individually and compare bioactivity of 
the intact ligand and the DPP4-cleaved ligand, based on recent research. We will also discuss why some 
results in this area have been misleading or hard to accurately interpret, and demonstrate what we 
believe are essential tools for better and more accurate experimental results in the future for this field.  
Problems related to the lack of understanding of these cryptic ligands include: 1. There are few tools to 
distinguish the ‘intact” ligand from the DPP4-cleaved ligand (or further proteolytically processed 
isoforms). Most antibodies to the ligands see both intact and N-terminal proteolytically cleaved isoforms 
equally well (Wang, et al., 2014); 2. Consequently the short half-life, on the order of minutes, for most 
DPP4 ligand substrates leads to almost universal misinterpretation of the amount of intact ligands 
relative to the DPP4 cleaved ligands, which means some activities attributed to “intact” ligands are in 
fact due to the DPP4-cleaved isoforms; 3. Without the timely use of DPP4 inhibitors, or other proteolytic 
inhibitors, DPP4 activity continues during the time required to obtain and process the sample before 
stabilization and storage, with both in vivo and in vitro samples (e.g. blood draws followed by serum or 
plasma collection; or tissue culture media collection). This creates a number of problems when 
subsequently attempting to quantify ligands from such samples. For example, the actual amount of 
intact ligand is reduced by DPP4 activity, and once DPP4 initiates N-terminal cleavage, this allows other 
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proteases to rapidly remove additional N-terminal amino acids accelerating the substrate’s degradation 
and clearance (Klemann, et al., 2016) leading to a significant reduction in the “total” amount of 
detectable ligand within a sample (Baerts, et al., 2015; Richter, et al., 2014). Complicating the problem 
of mismeasurement of “total” ligand isoforms is increased variability when DPP4 and other protease 
inhibitors are not used at the point of initial sample collection, a significantly increased portion of the 
remaining ligand isoforms collected are in the DPP4-cleaved state, or even further processed. This 
results in increased variability in sample ligand measurement, as well as variability in the identification 
and quantification of the different biologically active cleaved ligand isoforms (Baerts, et al., 2015).  
These challenges will be discussed in more detail below. 
In this review, we look at the effect that DPP4 proteolytic cleavage has on the activity and biological 
functions of five major DPP4 substrate peptide hormones. This review establishes a better 
understanding of the clinical relevance of DPP4 inhibitors, by focusing on the biological actions of the 
cleaved isoforms, which are significantly understudied and usually overlooked when compared to the 
biological actions of intact isoforms of different DPP4 substrates. We report the most recent findings in 
this field, and present evidence that DPP4-cleaved peptides are far more interesting, as well as 
translationally and clinically relevant, than initially thought. 
2. DPP4: 
2.1. DPP4 activity: 
Membrane associated and soluble DPP4 enzymes are responsible for cleaving several circulating 
substrates including peptide hormones and cytokines. This functional cleaving of dipeptides occurs at 
the N-terminal of the target substrate, by specifically cleaving off X-Proline and X-Alanine dipeptides 
from its polypeptide substrates (Lone, et al., 2010; Mabilleau, et al., 2013). Recently CD26/DPPIV is also 
recognized to cleave some substrates that include hydroxyproline, serine, glycine, valine, threonine, and 
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leucine in the second amino acid position (Havre, et al., 2008). CD26 forms homodimer complexes with 
the enzymatic activity residing in the extracellular portion and with each subunit containing an 
alpha/beta hydrolase domain together with an eight-bladed beta-propeller domain to form the 
substrate binding pocket (Rasmussen, et al., 2003). DPP4 is a member of a complex gene family that 
contains other enzymes responsible for cleaving other structurally related peptides. The DPP4-related 
enzymes include seprase, fibroblast activation protein α, DPP-6, -8, and -9, Attractin, and N-acetylated-
α-linked acidic dipeptidases I and II (Busek, et al., 2004; Frerker, et al., 2007; Gorrell, 2005). Over the last 
few years, DPP4 has been thoroughly investigated because of its impact on several crucial cytokines and 
peptides implicated in different medical conditions. One of the most studied DPP4 substrates is GLP -1. 
GLP-1 is a 30 amino acid long incretin peptide hormone essential for glucose metabolism. GLP-1 
enhances insulin secretion, which makes its role critical in the physiology and pathophysiology of 
diabetes. Normally, GLP-1 gets cleaved rapidly by DPP4 (Cantini, et al., 2017; Xu, et al., 2007). GLP-1–
based drugs, including GLP-1 agonists and DPP4 inhibitors have been recently introduced into clinical 
practice with much enthusiasm (Carr, et al., 2010; Mannucci, et al., 2005). 
In addition to its dipeptidase enzymatic activity, CD26 is also reported to have non-enzymatic functions 
mediated by molecular interactions with multiple binding sites in the beta-propeller domain (Havre, et 
al., 2008). CD26 can form heterodimers with fibroblast activation protein α, and to associate with 
plasminogen 2, adenosine deaminase (ADA), CD45, C-X-C chemokine receptor type 4 (CXCR4), and 
mannose 6-phosphate/insulin-like growth factor II receptor, as well as binding to extracellular matrix 
(ECM) glycoproteins such as fibronectin and collagen proteins (Havre, et al., 2008). DPP4 binding to ECM 
components may mediate turnover or modification of the ECM and DPP4 substrates near the cell 
surface. It permits soluble DPP4 to reside in specific ECM locations for either substrate interactions or 
DPP4 enzyme storage in the ECM reservoir for subsequent release from this pool, and attack of its 
substrates, upon ECM degradation during development, tissue maintenance or injury repair. A number 
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of ECM molecules, including collagens and glycoproteins are modified by proteases to yield novel 
matrikines, which are ECM molecule fragments that act as trophic and growth factors. Proteolytic 
modification of ECM molecules can also yield novel binding sites for integrins and other EM receptors 
called matricryptins (Ricard-Blum & Salza, 2014; Su, et al., 2016). If CD26 itself is not cleaving these ECM 
molecules directly it may be interacting with other proteases in regulating the creation of these 
molecules. The consequences of these interactions are unclear although they may serve to help rapidly 
modify ligands or binding partners of these molecules regulating signaling and adhesive interactions. 
Additionally, CD26 can internalize with some of these molecules, notably CD26 has been shown to bind 
CXCR4, the primary receptor for the cytokine/chemokine, and CD26 substrate, CXCL12 (Havre, et al., 
2008; Herrera, et al., 2001). When CXCL12 binds CXCR4 initiating signaling, the CXCR4/CXCL12/CD26 
complex can be internalized as part of the endosomal/lysosomal network. The exact function is not fully 
understood, but it may be part of the negative feedback regulation of the CXCL12/CXCR4 signaling 
pathway to temporally sharpen the end of the signal. The interaction of CD26 and CXCR4 will be further 
discussed in section 7.   
A naturally occurring loss of function mutation in the DPP4 gene helped identify the importance of the 
DPP4 enzyme. Fischer 344 (F344) rats have a Gly633-Arg mutation in the DPP4 gene. Although the 
mutant enzyme is synthesized normally, it is unable to be exported out of the endoplasmic reticulum, 
resulting in its rapid degradation. F344 rats showed a better glucose tolerance with higher GLP-1, GIP 
and insulin levels following an oral glucose challenge. The same results were demonstrated again in a 7-
week high-fat feeding F344 rat model, in addition to reduced weight gain. Overall, it was shown that loss 
of DPP4 activity in rats is associated with an increase in GLP-1 action (Erickson, et al., 1992; Thompson, 
et al., 1991; Tsuji, et al., 1992). 
DPP4 inhibitors have been intensely investigated gaining wide popularity as a therapeutic approach for 
diabetes. Until just few year ago, the majority of scientists believed that DPP4 inactivates peptide 
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hormones by cleaving them. However, recent data showed that this is not always the case. A study by 
Ban et al., reported that DDP4-truncated peptide hormones may still retain functional activity similar to 
the non-truncated peptides (Ban, et al., 2010). More interestingly, other studies demonstrated that the 
DPP4-truncated peptides have different receptor specificities leading to a modified activity different 
from the parent peptide (Gautier-Stein & Mithieux, 2013; Sparre-Ulrich, et al., 2017). Importantly, 
emerging research suggests the activity of some peptides is mainly attributed to the cleaved form 
instead of the intact or non-cleaved parent form (Deacon, et al., 2002). Understanding this crucial stem-
point would explain the heterogeneity of the results of many, previously performed studies. This review 
shows it is common, yet inaccurate, to simply attribute the experimental results to administrating the 
intact “non-cleaved” form of a DPP4 enzyme substrate.  Rather, further investigation can reveal that the 
results are in fact due to a proteolytically modified form of the administered ligand substrate.   
2.2. DPP4 substrates: 
The vast majority of research performed on DPP4 substrates is focused on the intact isoform of the 
substrate, as they are generally treated as being the sole bioactive form. This common assumption has 
resulted in a limited number of DPP4 substrates that have been well studied in terms of their proteolytic 
metabolic isoforms following DPP4 truncation, which is often the first proteolytic N-terminal step for 
DPP4 substrates (Klemann, et al., 2016). Since DPP4 inhibitors used in the clinic are for treating diabetes, 
most DPP4-related research focuses on the incretin hormones GLP-1 or GIP as the target ligand in 
diabetic models.  
We identified five major DPP4 substrates where research has focused on both their cleaved, as well as 
the intact, isoform (Table 1). Those ligand substrates include GLP-1, GIP, PYY, NPY, and CXCL12. Both 
GLP-1 and GIP are incretin hormones that are mainly involved in postprandial glucose level regulation 
(Nauck, 2013; Rehfeld, 1994). PYY and NPY belong to the polypeptide family of peptide hormones, and 
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they both regulate appetite and satiety centers in brain (Flynn, et al., 1998; Unniappan, et al., 2006). 
CXCL12 is a cytokine/chemokine and chemoattractant involved in regulating cell migration, homing of 
stem cells to injury sites, as well as the mobilization and recruiting of lymphocytes to sites of 
inflammation, or activated endothelium initiating cell attachment and diapedesis (Ghadge, et al., 2011; 
Guo, et al., 2015; Xue, et al., 2014; Yu, et al., 2016; Zhang, et al., 2017). CXCL12 mediates the movement, 
differentiation and function of numerous other cells including various stem cells, neurons, 
angioblast/endothelial cells and tumor cells during tissue development, maintenance and disease, as 
well as complex processes such as angiogenesis, hematopoiesis, and tissue protection and repair 
following injury (e.g. cardioprotection, tissue response to ischeamic stroke,  and bone repair) (Anderluh, 
et al., 2016; Bromage, et al., 2014; Cheng, et al., 2017a; Yang, et al., 2018).  
Table 1: DPP4 intact substrates, and their amino acid sequences 
Substrate  Amino acid sequence Ref. 
GLP-1(7-
36) 
HA ↑ EGTFTSDVSSYLEGQAAKEFIAWLVKGR 
(Orskov, 
et al., 
1989) 
GIP(1-42) YA ↑ EGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ 
(Sparre-
Ulrich, et 
al., 2017) 
PYY(1-36) YP ↑ IKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY 
(Grandt, 
et al., 
1994a) 
NPY(1-36) YP ↑ SKPDNPGEDAPAEDMARYYSALRHYINLITRQRY 
(Tatemot
o, 1982) 
CXCL12α(
1-67) 
KP↑VSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQE
YLEKALNK 
(Dong, et 
al., 2012) 
 
↑ DPP4 proteolytic site 
2.3: Troubleshooting the challenges in studying DPP4-cleaved substrates 
While the listed DPP4 substrates are thoroughly studied in their intact form, more limited, but an 
increasing amount of research has been conducted to investigate dose effects, signaling pathways, and 
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functions, related to their DPP4-cleaved forms. Furthermore, accurate interpretation of intact substrate 
research results is complicated by the common assumption by researchers that relates their outcome 
measures - any biological response or signaling event - to the intact form, without giving consideration 
to the idea that the cleaved form might at least partially be responsible for the observed effects.  
One issue that complicates research of DPP4 metabolic substrates is the lack of commercially-available, 
reliable, sensitive, and accurate quantification methods to detect and measure the cleaved isoforms or 
even distinguish them from the intact substrates. Rigorous research requires the ability to accurately 
quantify both intact and DPP4-cleaved ligands in both in vivo biological and in vitro samples. Since the 
difference between intact and DPP4-cleaved ligands is only 2 amino acids, finding or designing a good 
antibody that only reacts with one of the two forms is problematic. Until last year, only GIP out of the 
five mentioned DPP4 substrates had an antibody that can differentiate between intact or full length GIP, 
and DPP4-cleaved GIP, this antibody is utilized in an ELISA assay to quantify GIP(1-42)  (Troutt, et al., 
2011). In 2017, Bromage et al., managed to design a novel recombinant antibody that can be used in an 
ELISA assay to specifically quantify intact (non-DPP4 cleaved) CXCL12, with reportedly no cross-reactivity 
to DPP4-cleaved CXCL12 (Bromage, et al., 2017). Recently, our lab has generated a DPP4-cleaved CXCL12 
specific polyclonal antibody that does not cross-react with the intact form and can detect physiological 
levels of DPP4-cleaved CXCL12 (Elmansi, et al., 2018).  Other commonly available antibodies that 
recognize DPP4 substrates are intended to detect the intact (non-DPP4 cleaved) form, but have not 
been characterized as to whether they also recognize proteolytic isoforms, or if they have been 
characterized, they see the intact and multiple N-terminal proteolytic variants (Antonsson, et al., 2010; 
Baerts, et al., 2015; Bromage, et al., 2017; Richter, et al., 2014; Wang, et al., 2014). Quantification 
methods based on these antibodies misrepresent how much intact or cleaved ligand are in a biological 
sample and result in inaccurate or misleading results. A good example for misleading associations that 
resulted from not having the right quantification tools is the association between remote ischemic 
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conditioning (RIC) and upregulated levels of CXCL12 (Fortunato, et al., 2013; Jiang, et al., 2013; Kamota, 
et al., 2009). Using an inflatable cuff, RIC applied to either arms of healthy human volunteers, or to hind 
limps of Sprague-Dawley rats, and utilizing their new intact CXCL12-specific antibody; Bromage et al., 
demonstrated that although there is an upregulation in total CXCL12 levels as reported by previous 
literature, there is an unexpected significant decrease in intact CXCL12 levels after RIC, suggesting a 
dramatic increase in CXCL12 N-terminal cleavage following RIC and potentially flipping the interpretation 
of study results while revealing the presence of DPP4 isoforms that may themselves be influencing the 
results. Baerts et al, found similar results in ischemic heart disease (Baerts, et al., 2015).  These 
cautionary findings are applicable to all studies of DPP4 substrate ligands, but most especially where the 
metabolite products may have their own biological activity (Mulvihill & Drucker, 2014).  
To avoid the daunting challenge of designing an antibody that is specific for either the intact or DPP4-
cleaved ligand researchers turned to using different mass spectrometric techniques. Mass spectrometry 
(MS) characterizes and quantifies different peptides depending on their mass, making a two-amino acids 
difference easier to detect. The problem, however, is that in a complex biological sample, there is a vast 
pool of peptides that might share similar molecular weights. A second problem is the very low 
physiological concentration of some of the peptides in question are below the MS detection limits, 
resulting in the need  to artificially add superphysiological concentrations of the ligands to biological 
samples to produce enough of the intact and cleaved variants to be detected using standard MS (Busso, 
et al., 2005; De La Luz Sierra, et al., 2004). These two challenges in MS analytical methods have confined 
it for a long time to qualitative analysis, which is identification and characterization of different cleaved 
variants of specific peptides under very limited conditions (Richter, et al., 2014). To increase selectivity 
and obtain a lower physiological limit of detection, Chappell et al., utilized immunoaffinity enrichment 
MS with liquid chromatography sample purification to be able to quantify both GLP-1(7-36) and GLP-1(9-
36) in human plasma (Chappell, et al., 2014). Another pioneering paper is CXCL12 quantification by 
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Wang et al., followed the same general scheme to accurately quantify intact and DPP4-cleaved CXCL12 
in circulation of mice and rhesus monkeys (Wang, et al., 2014). Wang et al., found that a DPP4 inhibitor 
while decreasing total levels of CXCL12, measured through other commercially-available quantification 
methods, actually significantly increased levels of the intact CXCL12; a major unexpected  finding that 
demonstrates the importance of measuring intact and cleaved peptides in interpreting experimental 
data. This effect was speculated by the authors to represent a reduction in the overall amount of 
proteolytic isoforms while retaining or slightly increasing the amount of intact CXCL12. The inhibition of 
CXCL12 turnover results in negative homeostatic feedback regulation of the synthesis and release of 
CXCL12 by CXCR4+ cells that would normally increase CXCL12 synthesis when there is a reduction in 
intact CXCL12/CXCR4 signaling following proteolysis. The overall effect would be a decrease in total 
CXCL12 levels (Wang, et al., 2014).  
Even with having the right specific antibody, or the right immunoaffinity enrichment mass spectrometry 
protocol with a low enough limit of detection that works for biological samples, there is still the problem 
of very short half-life for some of these DPP4 substrates, and the importance of inhibition of DPP4 
proteolysis during sample handling to allow accurate measurement of the substrates and their 
metabolic products. Utilizing labeled peptides, Kieffer et al., demonstrated that more than 50% of GLP-1 
is metabolized in rats to DPP4-cleaved form within 2 minutes (Kieffer, et al., 1995). Antonsson et al., 
reported 80% of CXCL12 was cleaved in plasma by DPP4 within 5 minutes. Interestingly, they also 
showed that the DPP4 cleaved isoform has a significantly longer half-life than full length CXCL12 and 
consequently may have a longer time for its own biological actions to be induced than the intact ligand 
(Antonsson, et al., 2010). Baerts et al., analyzed immunoreactivity of CXCL12α in human plasma samples 
immediately after sample collection with, or without, DPP4 inhibitors in the collection tube. They 
showed a 25% decrease in the total amount of detectable CXCL12 when DPP4 was not inhibited at the 
time of collection. This would include not only intact CXCL12, but the DPP4-cleaved isoform and other 
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further proteolytic isoforms.  Importantly with further incubation (one hour) the total detectable 
CXCL12 dropped by 75% (Baerts, et al., 2015).  The results of this experiment and others show that ex 
vivo DPP4 proteolysis of CXCL12, and by extension other DPP4 substrates, can lead to misleading 
experimental data, both immediately at the time of collection or following the time needed for 
processing samples prior to analysis or storage (Antonsson, et al., 2010; Baerts, et al., 2015; Bromage, et 
al., 2017; Hall, 2014; Mortier, et al., 2011; Richter, et al., 2014; Wang, et al., 2014). This raises an 
important and generally overlooked point; when it comes to DPP4 substrates quantification, sample 
collection and handling can greatly affect results and lead to data misinterpretation. We recommend 
that specific DPP4 inhibitors such as sitagliptin or linagliptin should be used not only for sample 
collection and preservation but also used as an important control treatment group when analyzing 
results. We also recommend the potential addition of broad spectrum proteolytic cocktails in 
combination with DPP4 inhibitors to block further degradation of extant DPP4-cleaved substrate 
metabolites in samples. This will help dissect out the impact of the metabolites and see the “specific” 
effect of intact or cleaved ligands in animals and cell culture studies. Without the use of DPP4 inhibitors 
in an experiment, researchers are looking at the effect of mixed populations of intact and cleaved 
ligands on their outcome measures. If DPP4 substrates are used as treatments in experiments where the 
DPP4 metabolites may have separate bioactivity, the generation of those isoforms and their impact on 
outcome measures should be considered.  
All of these factors make the task of quantifying the cleaved or intact peptide challenging, and hence it is 
harder to establish an association between a certain biological function or trait, and appropriately 
assigning it to the intact ligand, the DPP4-cleaved ligand or a summing of effects from a combination 
isoforms. 
Another factor that interferes with both quantification of ligands, and interpretation of results; is 
binding of intact or cleaved forms to ECM molecules like glycosaminoglycans (GAGs). It was found that 
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both GLP-1 and GLP-2 can be stored in aggregates with GAGs (Maji, et al., 2009). Different GAGs have 
also been shown to bind CXCL12 and inhibit its cardioprotectitive effect (Peterson, et al., 2004; Ziarek, et 
al., 2013). This indicates that levels of other circulating factors like GAGs as well as GAGs in the 
extracellular microenvironment can affect the concentration and function of different cytokines and 
peptide hormones (Figure 1). Importantly this may impact the amount of DPP4 substrate ligands that 
are available to be measured both due to GAG-ligand binding removing them from the soluble pool to 
be quantified, as well as masking them from antibody-based assays by blocking antigenic sites targeted 
by the antibodies. Some investigators are now also trying to liberate GAG-bound DPP4-substrate ligands 
in samples prior to quantification to be able to assess the different ligand pools (Irhimeh, et al., 2007; 
Sweeney & Papayannopoulou, 2001).  
All of the previous factors demonstrate how complicated and challenging the study of DPP4 substrates 
can be. However, with the right experimental tools, study design, and data interpretation based on 
critical thinking, researchers have been able to start to show that many DPP4-cleaved peptides possess 
separate bioactivity from their parent peptides. In the next section, we will present their data and try to 
connect the dots between different results to form a better understanding of how DPP4 changes its 
substrates’ bioactivity. 
3. GLP-1: 
GLP-1(7-36) is a peptide hormone released from the L cells of the small intestine in response to food 
ingestion. GLP-1 hormone binds to the GLP-1 receptor (GLP-1R) and results in stimulating insulin 
secretion as well as inhibiting glucagon release. As a result , the blood glucose level usually decreases 
following  food ingestion (Nauck, 2013). GLP-1 possesses additional, non-gastrointestinal related effects. 
These effects include protection against post-myocardial infarction remodeling and inhibition of adipose 
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stem cells (ASC) differentiation. A higher dose of GLP-1 leads to significant inhibition of both ASC cell 
count and cell growth (Chen, et al., 2014; Goodwill, et al., 2014; Sauve, et al., 2010; Sokos, et al., 2006). 
Full length GLP-1 has a limited half-life prior to DPP4 cleavage. GLP-1 injected subcutaneously in beagle 
dogs has a short half-life of less than 60 minutes prior to being cleaved by DPP4 into GLP-1(9-36). In rats 
the half-life prior to DPP4 cleavage has been reported to be as short as 2 minutes (Kieffer, et al., 1995). 
For a long time, GLP-1(9-36) was considered to be inactive (Knudsen & Pridal, 1996). However, a recent 
study by Chen et al., showed that it possesses some of the functional activity of intact GLP-1 (Chen, et 
al., 2014).  
3.1. GLP-1 effect on postprandial glycemia: 
Studies have shown that exogenous administration of either intact or DPP4-cleaved GLP-1 to human 
subjects leads to reduction of both fasting and postprandial glucose levels. However, the effect of intact 
GLP-1 was different from the cleaved. It has been found that the cleaved form had minimal effect on 
reducing blood glucose levels, in addition that effect was only seen with the use of supraphysiological 
levels of cleaved GLP-1. In contrast, intact GLP-1 reduced blood glucose level much more efficiently and 
that effect was attributed to delaying gastric emptying and lowering glucagon levels. Cleaved GLP-1 had 
no significant effect on either gastric emptying or glucagon levels (Meier, et al., 2006; Vahl, et al., 2003).  
These findings were further confirmed by another study in pigs conducted by Deacon et al. The aim of 
the study was to assess the effect of cleaved GLP-1 on blood glucose levels. The study found that both 
intact and cleaved GLP-1 reduced blood glucose. They also suggested that cleaved GLP-1 works through 
enhancing the glucose disposal rate with no effect on insulin secretion (Deacon, et al., 2002). Another 
study by Cantini et al., was conducted to evaluate the effect of intact and cleaved GLP-1 on glucose 
uptake. To do that, they treated ASCs for 1 hour with 10 nM insulin in the presence or absence of 10 nM 
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of either intact or cleaved GLP-1. They found that both intact and cleaved GLP-1 significantly inhibited 
glucose uptake to a similar extent (Cantini, et al., 2017). 
Altogether, it has been strongly suggested that the cleaved GLP-1 form shares some effects with intact 
GLP-1, but has significant differences in how it achieves those effects. Interestingly, it has been reported 
that the cleaved form might be signaling and acting through receptors other than GLP-1R, which would 
explain the different mechanisms of action (Cantini, et al., 2016).  
 
3.2. GLP-1 effect on adipogenesis: 
Intact GLP-1 is known to inhibit ASC adipogenesis, and to downregulate the expression of adipocyte-
specific markers like adipocyte protein 2, lipoprotein lipase and peroxisome proliferator-activated 
receptor gamma (El Bekay, et al., 2016; Lee, et al., 2015). 
Cantini et al., evaluated the effect of intact and cleaved GLP-1 on ASC adipogenesis in vitro using Oil Red 
O and AdipoRed stains. Their results showed that treating ASCs with either intact or cleaved GLP-1 
reduced the number of differentiated adipocytes as well as cytoplasmic lipid droplets. Also, both intact 
and cleaved GLP-1 reduced mRNA expression of FABP4, an adipose differentiation marker. They found 
that exendin (9-39), a competitive antagonist of GLP-1R, was able to reverse only the intact GLP-1 effect, 
but not that of cleaved GLP-1. This suggests that both intact and cleaved GLP-1 are working through 
different receptors  (Cantini, et al., 2017) (Table 2). 
3.3. GLP-1 effect on apoptosis and cell proliferation: 
Both intact and cleaved GLP-1 significantly inhibited cell growth and decreased cell count. Exendin (9-39) 
itself did not affect cell numbers. However, it was able to reverse the decrease in cell numbers that was 
caused by intact GLP-1, but not cleaved GLP-1. Cytofluorimetric assays of annexin-V exposure on cell 
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surface showed that both intact and cleaved GLP-1 significantly induced cellular apoptosis and caused a 
significant increase in apoptotic ASCs. In addition, both forms inhibited cell proliferation as shown by 
results of MTT assays. Similarly, exendin (9-39) was able to reverse the apoptotic effect of the intact 
GLP-1 with no significant action on cleaved GLP-1’s effect (Cantini, et al., 2017). 
3.4. GLP-1 effect on the cardiovascular system: 
The effects of intact and cleaved GLP-1 on the cardiovascular system have been assessed in different 
models. Ex vivo, rat thoracic aortas were excised and cut into 3 mm rings to assess cumulative relaxation 
responses for both intact and cleaved GLP-1. Both intact and cleaved GLP-1 significantly relaxed the rat 
aorta vasculature in a dose-dependent manner (Green, et al., 2008).  
In vivo, intact GLP-1 is known to protect myocardial tissue from ischemic events, an effect that GLP-1R 
antagonist exendin (9-39) was not able to reverse. The myocardial protective effect of GLP-1 even 
persisted in GLP-1R knockout mice (Ban, et al., 2008; Sonne, et al., 2008). Cleaved GLP-1, on the other 
hand, was shown to be specifically protective against the development of diastolic dysfunction after 
myocardial infarction. It also reduced myocardial inflammation by affecting infiltrating macrophages. In 
addition, cleaved GLP-1 increased mitral valve E/A ratios, and decreased E wave deceleration rate in 
echocardiography in mice with myocardial infarction. These protective effects of cleaved GLP-1 were not 
reversed by exendin (9-39) (Robinson, et al., 2016). Accordingly, it is now starting to be thought that this 
protective effect against cardiac ischemia can be attributed exclusively to cleaved GLP-1, and that 
previously it was mistakenly attributed to intact GLP-1. An experiment that proved this point was 
conducted by Ban et al., where sitagliptin, a DPP4 inhibitor, was used to prevent the truncation of the 
intact GLP-1 resulting in diminished intact GLP-1 protective effects against ischemia (Ban, et al., 2008; 
Sonne, et al., 2008).  
3.5. GLP-1R Receptor binding: 
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Based on findings of the studies mentioned above, cleaved GLP-1 possesses physiological actions that 
are not inhibited by blocking the GLP-1R or knocking down its expression. This suggests that cleaved 
GLP-1’s actions may be through another pathway independent of the classical GLP-1R pathway (Figure 
2). This provides a strong rationale to perform receptor binding assays of both intact and cleaved GLP-1 
to GLP-1R. These studies will be essential in the interpretation of various experimental results. 
To determine affinity and binding density of both intact and cleaved GLP-1 to GLP-1R, Kuc et al., 
performed radioligand binding assays on coronal sections of mouse brain. These sections were selected 
since the tissues have high expression levels of GLP-1R as indicated by the localized in situ hybridization 
expression of its mRNA. Their results showed that both binding affinity (KD) and binding density (BMAX) of 
cleaved GLP-1(9-36) to GLP-1R in mouse brain coronal sections were significantly lower than intact GLP-
1(3-36). Moreover, scintillation proximity assays (SPA) showed differential binding of intact and cleaved 
GLP-1 to GLP-1R. Based on SPA, the affinity of cleaved GLP-1 to GLP-1R receptor (Ki) was 70,000-fold less 
than intact GLP-1. Finally, cAMP assays were performed in CHO-K1 cell line expressing wild type GLP-1R 
receptors to evaluate receptor activation. In line with minimal association and binding of cleaved GLP-1 
to the GLP-1R receptor, the cAMP assay results showed minimal signaling activation of GLP-1R by 
cleaved GLP-1. The maximum intracellular signaling  of cleaved GLP-1 (EMAX) was 10% of the intact form, 
and an agonist response curve showed that almost 105 fold increase in cleaved GLP-1(9-36) 
concentration was required to reach this EMAX as shown by EC50 values (Kuc, et al., 2014) (Table 3). This 
supports the idea that most - if not all - of cleaved GLP-1’s biological effects are mediated through a 
different receptor than GLP-1R. 
3.6. GLP-1 summary: 
While DPP4-cleaved GLP-1(9-36) displays some of the intact ligand’s biological functions, we believe that 
the cleaved form is acting through a different mechanism than intact GLP-1(7-36) since the effects are 
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not blocked by GLP-1R inhibitors like exendin or by knock-down of the receptor. Of all the important 
biological functions that intact GLP-1 influences, such as decreasing ASCs count and proliferation, 
increasing apoptosis, and downregulating glucose uptake, we think there is evidence that GLP-1’s 
myocardial protective function against ischemic events and diastolic dysfunction is in fact due to DPP4-
cleaved GLP-1(9-36) mediated through a receptor other than GLP-1R. 
 
 
Table 2: Biological functions of intact and cleaved GLP-1 alone and with exendin(9-39) (GLP-1R 
blocker) 
 Intact GLP-1(7-36) Cleaved GLP-1(9-36) Ref. 
Effect Alone 
With 
exendin(9-39) 
Alone 
With 
exendin(9-39) 
 
Cell count Decrease No decrease Decrease Decrease 
(Cantini, et al., 
2017) 
Cell 
proliferation Decrease ND Decrease ND 
(Cantini, et al., 
2017) 
Apoptosis Increase ND Increase ND 
(Cantini, et al., 
2017) 
Adipogenesis Decrease No decrease Decrease Decrease 
(Cantini, et al., 2017; 
El Bekay, et al., 
2016) 
Glucose 
uptake Decrease ND Decrease ND 
(Cantini, et al., 
2017) 
Myocardial 
protective  
effects 
Increase Increase Increase Increase 
(Robinson, et al., 
2016; Sonne, et al., 
2008) 
ND: not determined 
Table 3: Receptor binding assays of intact and cleaved GLP-1 to GLP-1R 
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 Intact GLP-1(7-36) Cleaved GLP-1(9-36) Ref. 
Saturation binding assay KD 1.29 ± 0.26 AU 0.214 ± 0.08 AU (Kuc, et al., 2014) 
Saturation binding assay BMAX 57.0 ± 14.5 AU 2.69 ± 0.74 AU (Kuc, et al., 2014) 
SPA binding assay Ki 0.102 nM 156 nM (Kuc, et al., 2014) 
cAMP assay EC50 0.072 nM 7270 nM (Kuc, et al., 2014) 
cAMP assay EMAX 104% 8.93% (Kuc, et al., 2014) 
 
 
4. GIP: 
GIP is a 42 amino acid long peptide hormone. It is synthesized by enteroendocrine K-cells of the stomach 
and duodenum. Similar to GLP-1, GIP is responsible for regulation of postprandial glycemia (Rehfeld, 
1994). Structurally, the C-terminal domain is dispensable for GIP effects. As a matter of fact, the 
functional activity of GIP wasn’t reduced after removing three to four amino acids from the C-terminal. 
Moreover, the GIP(1-31) fragment, missing 11 amino acids from the C-terminal, was still able to retain 
cAMP stimulatory effect equal to that of intact GIP (Fujita, et al., 2010a; Fujita, et al., 2010b). On the 
contrary, the N-terminal is critical for the activity of GIP-1. It has been found that while recombinant GIP 
missing 4 amino acids from the N-terminal domain was able to bind to the receptor with a similar 
affinity to the intact form, its insulintropic activity was significantly reduced (Hinke, et al., 2001). As a 
DPP4 substrate, DPP4 truncates GIP peptide at its N-terminal by removing the two terminal amino acids. 
Lacking the N-terminal essential for its signaling activity, cleaved GIP was believed to be biologically 
inactive (Deacon, 2004; Kieffer, et al., 1995). However, its ability to still bind the receptor suggests it 
may act as a competitive inhibitor. 
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Normally GIP is cleaved on both the N and C terminals though depending on the cleavage site the 
activity of the resulting fragment significantly varies. We are going to be discussing how DPP4 N-
terminal cleavage affects both intact GIP(1-42) and C-terminal cleaved GIP(1-30), converting them into 
GIP(3-42) and GIP(3-30), respectively. 
4.1. GIP effect on Glucose regulation:  
In ob/ob mice, intact GIP(1-42) results in decreased plasma glucose after glucose administration. In 
contrast GIP(3-42) leads to an initial increase in glucose reaching its peak after 15 minutes, before it 
starts to decrease. Administration of other N-terminal cleaved GIP isoforms to ob/ob mice, like GIP(8-
42), also showed a significant inhibition to intact GIP glucose lowering effect (Kerr, et al., 2011). 
4.2. GIP effect on Insulin secretion: 
In pancreatic BRIN-BD11 cells, intact GIP stimulated insulin secretion in a dose-dependent manner. GIP 
(3-42) on the other hand significantly decreased insulin secretion along with other N-terminal truncated 
variants including GIP(4-42) and GIP(8-42). When intact GIP was co-administered with GIP(8-42), 
another N-terminal truncated variant, GIP(8-42) significantly decreased intact GIP-induced insulin 
release at 15 and 30 minutes after administration. Also, when cells were incubated with either GIP(3-42) 
or GIP(8-42), together with intact GIP, insulin secretion stimulated by intact GIP was significantly 
inhibited (Kerr, et al., 2011). This could mean either that N-terminal truncated GIP variants possess an 
antagonistic effect to intact GIP through the same receptor by competitive inhibition, or via another 
unidentified receptor. 
In vivo, treatment with different variants of N-terminal truncated GIP did not significantly alter plasma 
insulin response after glucose injection in ob/ob mice, while intact GIP significantly increased plasma 
insulin level (Kerr, et al., 2011). In isolated perfused rat pancreas, GIP(3-30) competitively inhibited 
GIP(1-42) insulin, glucagon, and somatostatin secretion (Sparre-Ulrich, et al., 2017) (Table 4). The reason 
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for different results in isolated perfused rat pancreas versus the whole mice is not explained, but it could 
be due to the fact that in vivo serum insulin level is more tightly controlled than secreted insulin level in 
an isolated pancreas.  
4.3. GIP effect on cAMP response:  
In terms of receptor activation, Hansen et al showed that cAMP activation in response to GIP receptor 
activation was almost the same for both GIP (1-42) and GIP(1-30) in COS-7 cells, which are fibroblast-like 
cell lines derived from monkey kidney tissue. This suggests that the C-terminal of GIP is not essential for 
GIP receptor activation and down-stream responses. However, Kerr et al., found that DPP4 N-terminal 
truncated GIP (3-42) had a significantly lower cAMP expression, when compared to intact GIP in BRIN-
BD11 cells (Hansen, et al., 2016; Kerr, et al., 2011). This shows again that the N-terminal is necessary for 
receptor activation and subsequent cAMP activation, and that cleavage of N-terminal leads to loss of 
signaling events downstream to GIP receptor activation. However, the mechanism of ligand inactivation 
versus antagonism is important to distinguish.  
4.4. GIP receptor binding: 
Hansen et al., demonstrated that the N-terminal was critical for high-affinity binding to GIP receptor 
(GIP-R). The C-terminal on the other hand was a modulator for agonistic versus antagonistic actions 
(Figure 3). It was found that GIP(3-30) acted as a GIP-R antagonist in both human and rat cells. GIP(3-30) 
competitively inhibited GIP receptor activation by the intact form GIP(1-42). A very interesting finding 
was that although GIP(3-42) did not possess any agonistic activity, it was a significantly less potent 
antagonist than GIP(3-30) both in human and rat systems, suggesting that the C-terminal can be acting 
as a negative regulator of the antagonist action. Competitive binding assays for GIP(1-30) and GIP(3-30) 
were performed to compare affinity of both ligands to the GIP-R. It was found that DPP4-cleaved GIP(3-
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30) had a lower log(IC50) and higher Ki, suggesting it had a higher affinity to bind to the GIP-R than GIP(1-
30) (Hansen, et al., 2016) (Table 5).  
4.5. GIP summary: 
GIP is one of the most intriguing DPP4 substrates. While intact GIP(1-42) is a critical incretin hormone 
that increases insulin and glucagon secretion, N- and C-terminals cleaved GIP(3-30) results in strong 
antagonism to GIP-R mediated functions. It is believed that the N-terminus, cleaved by DPP4, controls 
whether GIP variants are agonistic or antagonistic to GIP-R signaling, while the C-terminus controls the 
strength of the antagonistic effect of the N-terminal DPP4 cleaved GIP on the GIP-R.  
 
Table 4: Effect of C-terminal and N-terminal cleavage on receptor binding and biological functions of 
GIP  
Effect GIP(1-42) GIP(3-42) GIP(1-30) GIP(3-30) Ref. 
GIP Receptor binding High Low High High (Hansen, et al., 2016) 
Receptor activity Agonist 
Weak 
antagonist 
Agonist 
Strong 
antagonist 
(Hansen, et al., 2016) 
cAMP production Increase Decrease Increase Decrease (Kerr, et al., 2011) 
Insulin secretion Increase Decrease Increase Decrease 
(Kerr, et al., 2011; 
Sparre-Ulrich, et al., 
2017) 
 
Table 5: Receptor binding assays of GIP(1-30) and GIP(3-30) to GIP receptor 
 GIP(1-30) GIP(3-30) Ref. 
Competitive 
binding assay 
-9.05 ± 0.02 AU -8.63 ± 0.04 AU (Hansen, et al., 2016) 
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logIC50 
Competitive 
binding assay Ki 
0.89 nM 2.3 nM  (Hansen, et al., 2016) 
 
5. PYY: 
PYY is a 36 amino acid member of the PP-fold family of peptide hormones. It is released from the distal 
intestine along with GLP-1 during digestion (Adrian, et al., 1985). This family of peptides act 
preferentially through binding specific receptors known as Y1, Y2, Y4, Y5, and Y6. Similar to the intestine, 
PYY is also expressed in the brain, where it binds at least three PYY receptors (Y1, Y2, and Y5) with 
different affinities (Blomqvist & Herzog, 1997). PYY exerts a wide variety of physiological actions, the 
most distinct being its ability to decrease appetite and inhibit food intake. In addition, it also inhibits 
gastrointestinal motility, gastric and pancreatic secretions, decreases glomerular filtration rate and 
promotes vasoconstriction (Ferrier, 2000; Playford, et al., 1992; Playford, et al., 1995; Yang, 2002). 
5.1 Y receptors subtypes: 
The different actions of PYY are achieved through binding to different receptors.  Y1 and Y5 activation is 
responsible for triggering hunger and increasing appetite. Interestingly, Y2 receptor activation decreases 
appetite and consequently decreases body weight in mice (Gerald, et al., 1996). Another main functional 
contrast between Y1 and Y2, is that Y1 specific agonists decrease anxiety, while Y2 specific agonists are 
anxiogenic. Receptors also vary in their distribution pattern within different tissues. Y1 receptor is 
expressed in adipocytes, colon, vascular smooth muscles, and the cerebral cortex (Castan, et al., 1993; 
Dumont, et al., 1990; Grundemar, et al., 1992; Mannon, et al., 1994). It is involved in the regulation of 
decreased anxiety and depression (Caberlotto, et al., 1999; Wahlestedt, et al., 1993). The Y2 receptor is 
expressed in nerve fibers, the hippocampus, and intestine (Gehlert, et al., 1992; Rettenbacher & Reubi, 
2001; Stjernquist & Owman, 1990), and it is associated with memory retention and angiogenesis (Flood 
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& Morley, 1989; Zukowska-Grojec, et al., 1998). The Y5 receptor is expressed in the hypothalamus, 
intestine, ovary, testis, pancreas, and skeletal muscle (Gerald, et al., 1996; Herzog, et al., 1997). It is 
involved with stimulation of appetite, and regulation of brain seizures and circadian rhythm (Gerald, et 
al., 1996; Gribkoff, et al., 1998; Guo, et al., 2002; Matsumoto, et al., 1996). 
DPP4 cleaves PYY (1-36) and yields PYY (3-36). PYY (3-36) has been proven to possess a distinct biological 
activity. Grandt et al., showed that DPP4-cleaved PYY(3-36) is a selective Y2 receptor agonist, as 
compared to intact PYY(1-36) that binds to both Y1 and Y2 receptors (Grandt, et al., 1994b). This shows 
a very interesting effect for DPP4 on PYY, where it shifts it from a limited-selective multi-receptor 
agonist that binds to three different Y receptors, to a highly selective agonist that binds only to one of 
these receptors. Based on that, there is a great chance that cleaved PYY (3-36) would be able to show a 
more prominent pattern of Y2 receptor activation compared to PYY (1-36). Therefore, DPP4 may be 
implicated in physiological control of appetite, by decreasing hunger-triggering Y1 and Y5 receptor 
signals, and upregulating anxiogenic Y2 receptor signal. Further studies, however, need to be conducted 
to support this hypothesis, and to test if pharmacological DPP4 inhibitors lead to increased food intake 
by downregulating PYY(3-36) protein levels and how this might interact with DPP4 mediated insulin and 
glucose regulation. 
5.2. PYY effect on food intake: 
According to a study conducted by Unniappan et al., they showed that in normal rats, both PYY (1-36) 
and PYY (3-36) significantly reduced 24-h food intake. In contrast, in DPP4 deficient rats, PYY(3-36) 
significantly reduced 24-h food intake, while PYY(1-36) had no notable effect (Unniappan, et al., 2006) 
(Table 6). This result suggests another instance where the effect of the DPP4-cleaved substrate may be 
mistakenly attributed to an intact form of the parent ligand. Without proper inhibition of the degrading 
enzyme, effects of both intact and cleaved form may be confused (Figure 4).  
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After fasting, DPP4 deficient rats also showed a higher 24-h food intake and weight gain. They also 
showed higher cumulative food intake during light phase and dark phase (Unniappan, et al., 2006). It has 
been also shown that treatment with PYY(3-36) through various routes of administration in different rat, 
mouse, and rhesus monkey models, in addition to obese humans, lead to reduction of food intake 
(Batterham, et al., 2003; Chelikani, et al., 2005; Moran, et al., 2005; Pittner, et al., 2004; Tschop, et al., 
2004). Taken together, these results support the idea that inhibition of food intake may in part be 
caused by the DPP4-cleaved form of PYY (3-36). 
5.3. PYY effect on GIT motility: 
Moriya et al., showed that PYY (3-36) - in addition to other Y2 receptor agonists – significantly inhibited 
castor oil-induced diarrhea in a dose-dependent manner in mice. PYY (3-36) also significantly blocked 
16,16-dimethyl Prostaglandin E2-induced intestinal fluid accumulation. It also significantly and dose-
dependently reduced wet fecal weight and bead expulsion time by slowing colonic transit (Moriya, et al., 
2010). This is an effect that was not reported for PYY(1-36). This could be because PYY(3-36) is a pure Y2 
receptor agonist, while the effects of PYY(1-36) is the result of Y1, Y2, and Y5 activation, which dilutes 
the overall effect producing a less distinct phenotype. 
5.4. PYY effect on locomotor and exploratory behavior: 
PYY (3-36) effects are not only restricted to food intake and GIT motility. Stadlbauer et al., showed that 
mice treated with PYY (3-36) show increased novel object exploration compared to vehicle treated mice. 
Also, mice treated with PYY (3-36) showed a higher locomotor habituation response to novel 
environments than mice treated with vehicle alone. PYY (3-36) potentiated the increase in locomotor 
response to amphetamine, as measured by the distance moved in an open field. Apomorphine 
treatment induces stereotyped behavior in mice, which is evidenced by increased leaning and climbing. 
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PYY(3-36) also increased this stereotyped apomorphine behavior (Stadlbauer, et al., 2013). These effects 
are also believed to be a result of Y2 receptor activation in the brain.  
5.5. PYY summary: 
Intact PYY(1-36) activates 4 different receptors (Y1, Y2, Y4, and Y5), and as expected, the biological 
effects from activating these 4 different receptors is complicated and hard to accurately measure 
compared to PYY(3-36) which appears to work as a Y2-specific receptor agonist. The only well 
documented biological function where PYY(1-36) is compared to PYY(3-36) is the effect on food intake. 
Both intact and cleaved variants decrease 24-h food intake in rats, and only PYY(3-36) decreases 24-h 
food intake in DPP4-deficient rats. This suggests that the decrease in food intake following intact PYY(1-
36) delivery is actually due to the DPP4 cleavage yielding PYY(3-36) after treatment in rats. Cleaved PYY 
also possesses other important biological activities on GIT mobility, and CNS mediated locomotor and 
exploratory behavior in mice. A better understanding of these functions as well as other possible effects 
of cleaved and intact PYY and interaction with other DPP4 cleaved substrate signal ing pathways is 
necessary to assess benefits and drawbacks of using clinical DPP4 inhibitors for treatme nt of diabetic 
patients or in other populations. 
Table 6: Receptor selectivity and effect on food intake of intact and cleaved PYY 
 Intact PYY(1-36) Cleaved PYY(3-36) Ref. 
Receptor 
selectivity 
Y1, Y2, Y4, and Y5 
agonist 
Y2 agonist (Grandt, et al., 1994b) 
Food 
intake 
Decrease  
(no effect on DPP4-
deficient mice) 
Decrease  
(acts on DPP4-
deficient mice) 
(Batterham, et al., 2003; Chelikani, et al., 
2005; Moran, et al., 2005; Pittner, et al., 
2004; Tschop, et al., 2004) 
 
6. NPY: 
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NPY is another 36 amino acid peptide hormone that is a Y receptor family agonist. Similar to PYY, it is 
expressed in the hypothalamus and is truncated by DPP4 to also produce a selective Y2 receptor agonist. 
NPY (1-36) increases short term 2-h food intake. In addition, NPY inhibits osteoblast activity centrally by 
binding to the Y2 receptor and peripherally by binding to Y1 receptor. NPY also affects adiposity both 
centrally in the hypothalamus and peripherally. Centrally, NPY increases fat accretion through Y1 and Y5 
receptors leading to increased bone marrow adiposity, and decreases bone marrow fat accretion 
through the Y2 receptor. Bone marrow and peripheral adiposity are differentially regulated, therefore it 
is interesting that in peripheral tissues, NPY leads to increased fat accretion through activation of both 
Y1 and Y2 receptors. NPY also plays a role in increasing adhesion and chemotaxis of macrophages. It also 
contributes in synaptic transmission and modulates neuroplasticity. NPY affects a complex 
interdigitating network of biological functions through four different receptors, and a better 
understanding of how DPP4-cleaved PYY is contributing to this complex network is essential to grasp the 
extents to which DPP4 inhibitors are affecting neuropeptide biology.  
6.1. NPY receptor binding: 
In 1996, Grandt et al., found that both NPY(1-36) and NPY(3-36) compete in binding to CHP 234 human 
neuroblastoma cells; a type of cell that expresses the Y2, but not the Y1 receptor, on their surface. 
However, SK-N-MC human neuroblastoma cells, which in contrast express Y1 receptor, but not the Y2 
receptor, only bind NPY(1-36). These results suggest that similar to PYY; the intact form is a non-
selective agonist for both Y1 and Y2 receptors, while the cleaved form is a selective Y2 agonist (Grandt, 
et al., 1996). 
6.2. NPY effect on Cell migration: 
It has been found by Ghersi et al., that both NPY(1-36) and NPY(3-36) cause human umbilical vein 
endothelial cells (HUVECs) to migrate in a wound healing model. However, when DPP4 activity was 
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inhibited using a DPP4 neutralizing mAb the anti-migratory effect of NPY(1-36) was significantly 
decreased. This suggests that increasing cell migration in wound healing model may be due to DDP4 
cleaved NPY(3-36) rather than the intact form (Ghersi, et al., 2001) (Table 7). 
Moreover, Singh et al reported that in the hematopoietic microenvironment, DPP4-cleaved NPY(3-36) 
reduced VE-cadherin and CD31 expression in endothelial cell junctions, and mobilized hematopoietic 
stem and progenitor cells (HSPCs) through Y2 and Y5 receptor activation. HSPCs trafficking was impaired 
in mice lacking either DPP4 or NPY, and was restored upon treatment of mice with DPP4-cleaved NPY(3-
36) (Singh, et al., 2017). 
6.3. NPY(3-36) effect on Food intake: 
The effect of NPY(3-36) on food intake has not been as thoroughly studied as PYY(3-36). One publication 
comparing NPY(1-36) to NPY(3-36) in rats in the context of food intake showed that NPY(3-36) leads to a 
greater increase in 2-hour food intake compared with NPY(1-36). The increase in food intake was found 
to be dose-dependent and it plateaued as the dose increased beyond 2.5 µg/rat (Flynn, et al., 1998) 
(Table 7). This is an unexpected result, and is in contrast to the effects of PYY(3-36) on food intake. An 
explanation for why NPY(3-36), a Y2 selective agonist, leads to increased food intake is unclear, and 
further work needs to be done to assess this effect of NPY(3-36) on a longer timeline. This suggests 
DPP4-cleaved PYY and NPY can differentially act on the Y2 receptor. 
6.4. NPY summary: 
NPY is not as thoroughly studied as GLP-1 or GIP, but it has been shown that intact NPY(1-36) can 
activate 4 different Y receptors (1, 2, 4, and 5) while DPP4-cleaved NPY(3-36) only activates the Y2 
receptor. Both NPY(1-36) and (3-36) induce HUEVCs migration, but with DPP4 inhibition, only NPY(3-36) 
retains this effect, which suggests that NPY(1-36) can only induce cell migration after being cleaved by 
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DPP4. Also, the effect of NPY on food intake is limited, however, in 2-h food intake studies DPP4-cleaved 
NPY(3-36) shows a greater inhibition of intake in rats compared to intact NPY(1-36). 
Table 7: Receptor selectivity and effect on cell migration and food intake of intact and cleaved NPY 
 Intact NPY(1-36) Cleaved NPY(3-36) Ref. 
Receptor 
selectivity 
Y1, Y2, Y4, and Y5 agonist Y2 agonist 
(Grandt, et al., 
1996) 
Cell migration 
+  
(effect blocked with DPP4 
inhibition) 
+ 
(effect retained with DPP4 
inhibition) 
(Ghersi, et al., 2001) 
2 Hour food intake + ++ (Flynn, et al., 1998) 
 
7. CXCL12, Stromal Cell-Derived Factor 1 (SDF-1) 
SDF-1/CXCL12 is a highly conserved pleiotropic chemokine/cytokine that is considered one of the 
earliest cytokines evolutionarily (Shirozu, et al., 1995). It is produced by numerous cell types and tissues 
constitutively and its expression is induced by most tissues in response to injury (Herberg, et al., 2013b). 
Common sources are tissue stromal/support cells such as mesenchymal derived cells involved in stem 
cell niche organization, cardiomyocytes, neural stem cells (NSCs), osteogenic cells,  and endothelial cells 
(Carbone, et al., 2017b; Herberg, et al., 2013b; Mortensen & Hill, 2015). For example, we and others 
have shown that in the brain astrocytes are the primary constitutive source of CXCL12.  Astrocytes 
increase CXCL12 secretion during development regulating neuronal cell and process migration, as well 
as in maintenance of the organization of the adult neurogenic zone, and critically in tissue repair 
following injury (Hill, et al., 2004; Miller, et al., 2005; Shin, et al., 2014). CXCL12 is also highly secreted by 
lung and bone marrow stromal cells,  as well as  stromal and endothelial  cells in other tissues being 
involved in a large spectrum of biological and developmental processes (Bleul, 1996; Nagasawa, et al., 
1996). CXCL12 is involved with cardioprotection, bone repair, neuronal regeneration, tumor cell 
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mobilization, migration and homing/metastasis (Bromage, et al., 2014; Broxmeyer, et al., 2005; Cheng, 
et al., 2017a; Li, et al., 2007; Yang, et al., 2018). On the cellular level, CXCL12 affects migration, survival, 
and proliferation (Herberg, et al., 2013a; Leite Pereira, et al., 2018; Reid, et al., 2018). In humans CXCL12 
has six alternative splice variants (α to φ) differing only in the exon related to the C-terminus. Out of 
these six, the most common splice variants are CXCL12α (1-68) and CXCL12β (1-72) (Yu, et al., 2006). All 
CXCL12 variants, including CXCL12α and CXCL12β, are cleaved by DPP4 removing their N-terminus KP 
dipeptide amino acids (Lambeir, et al., 2001; Shioda, et al., 1998). Importantly, the ability to initiate the 
DPP4 attack is regulated by the C-terminus. CXCL12 is rapidly cleaved when its C-terminal lysine is 
removed by Carboxypeptidase M or N, in contrast the half-life of the N-terminal intact CXCL12is longer 
due to the protection of lysine 68 by the four additional C- terminal amino acids blocking the binding of 
the carboxypeptidases (Herberg, et al., 2013a; Herberg, et al., 2013b). Other than difference in half-life, 
there seems to be no significant difference in receptor selectivity or functions between CXCL12α and 
CXCL12β (De La Luz Sierra, et al., 2004; Herberg, et al., 2013a; Herberg, et al., 2013b; McQuibban, et al., 
2001; Proost, et al., 1998; Richter, et al., 2014; Vergote, et al., 2006). Interestingly for CXCL12, not only 
does DPP4 cleave two amino acids from its polypeptide structure, but it sets CXCL12 up for further 
proteolysis by other peptidases that lead to even more circulating proteolytic metabolites of CXCL12 
(Richter, et al., 2014). Until recently DPP4-cleaved CXCL12 has generally been thought to be inactive, or 
at least much less active than intact CXCL12 (Anderluh, et al., 2016; Crump, et al., 1997; Shioda, et al., 
1998).  
The two main receptors for CXCL12 are CXCR4, a ligand concentration biased G-protein coupled 
receptor (GPCR), and CXCR7 (AKA - Atypical Chemokine Receptor 3 or ACKR3), a β-arrestin associated 
receptor that has a 1000-fold higher affinity for CXCL12 than CXCR4 (Quinn, et al., 2018; Reid, et al., 
2018; Sanchez-Martin, et al., 2012). Data suggests that both receptors can homodimerize, as well as 
heterodimerize with each other, or with other receptors including α1A/B-adrenoceptors (Decaillot, et 
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al., 2011; Levoye, et al., 2009; Tripathi, et al., 2015). This ability to dimerize regulates receptor functions 
and affects their downstream signaling events (Ferre, et al., 2014; Milligan, et al., 2007; Rozenfeld & 
Devi, 2010; Tripathi, et al., 2015). ACKR3 may have additional heterodimerization partners including 
epidermal growth factor receptor (Salazar, et al., 2014). The potential for multiple heterodimeric 
complexes with CXCL12 receptors opens the door for possible combinations that respond to DPP4, and 
other N-terminal, cleaved CXCL12 isoforms. The ligand, CXCL12, can itself homodimerize, and it can 
activate the CXCR4 receptor either in monomeric or a dimeric form (Drury, et al., 2011; Roy, et al., 
2015). There is, however, a ligand bias associated with CXCR4 response to monomeric or dimeric CXCL12 
activation. In this case, monomeric CXCL12 activation of CXCR4 leads to G-protein-dependent signaling. 
However, as the CXCL12 ligand concentrations increase, the likelihood of both ligand binding pockets of 
the CXCR4 receptor dimer being occupied increases as well. This is accompanied with a switch from 
GPCR-mediated signaling to β-arrestin-dependent signaling, which blocks actin remodeling and inhibits 
cell migration (Drury, et al., 2011; Ziarek, et al., 2017).  
 
7.1. Receptor activation by DPP4-cleaved CXCL12: 
Crump et al., assessed the ability of N-terminal modified, and other CXCL12 variants, to bind to and 
activate CXCR4 demonstrating that removal of the first 2 amino acids or beyond dramatically inhibited 
or eliminated binding to and activation of CXCR4 (Crump, et al., 1997). More recently, Janssens et al., 
used CXCR4-transfected, ACKR3-negative CHO and COS-7 cells to test receptor activation and signaling 
specifically through the CXCR4 receptor. It was found that starting at 100 pM, intact CXCL12(1-68) 
induced IP3 accumulation in the cytosol, and triggered phosphorylation of the second messengers ERK 
and Akt, in a dose-dependent manner. In contrast DPP4-cleaved CXCL12(3-68) even at concentrations up 
to 100 nM, did not induce IP3 accumulation, or ERK and Akt phosphorylation (Janssens, et al., 2017). 
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Janssens et al., also demonstrated that while DPP4-cleaved CXCL12α cannot activate CXCR4, it can still 
recruit β-arrestin through activation of the ACKR3 receptor. However, the activation of ACKR3 is about 
10-fold less than that induced by intact CXCL12 (Janssens, et al., 2017) (Table 8). Cheng et al., showed 
very similar results using the Presto-Tango β-arrestin 2 recruitment assays for CXCL12(1-68) and 
CXCL12(3-68). The assays showed that while 1 µM CXCL12(1-68) recruited β-arrestin 2 through both 
CXCR4 and ACKR3, CXCL12(3-68) only managed to recruit β-arrestin 2 through the CXCR4 receptor at 
extremely high doses in vitro [EC50 (nM) >10
3) with no detectable efficiency% while the ACKR3 receptor 
binding  of CXCL12 (3-68) lead to ACKR3 recruitment of β-arrestin 2 that was significantly greater [EC50 
(nM) >13.3±13.5), but reduced to about 20% efficiency compared to intact CXCL12(1-68) (Cheng, et al., 
2017b). Ziarek et al., 2017 also reported that DPP4-truncated CXCL12(3-68) shows a dramatic drop in 
CXCR4 binding affinity, in addition to complete loss of G protein agonist activity. They also described 
that cleaved CXCL12 possesses a very weak CXCR4 GPCR antagonistic activity (Ziarek, et al., 2017). 
Research done by Szpakowska et al., on CXCL11, another cytokine that activates CXCR3 and ACKR3, and 
is cleaved by DPP4 in a fashion similar to CXCL12, showed that DPP4-cleaved CXCL11 loses its ability to 
activate the CXCR3 receptor, but retains the ability to bind and activate ACKR3 (Szpakowska, et al., 
2018). This result, along with the previously mentioned CXCL12 receptor binding and activation assays, 
shows that removal of N-terminal lysine/proline by DPP4 is not able to initiate GPCR-biased activity 
through CXCR4, but can still induce β-arrestin mediated activity through ACKR3 and possibly to a lesser 
extent through CXCR4 β-arrestin mediated activity.  
7.2. CXCL12 GAG binding affinity: 
As mentioned previously, CXCL12 concentration and biological activity are affected by binding to GAGs. 
Janssens et al., utilized heparan sulfate and dermatan sulfate coated plates to compare the binding 
affinity of intact and cleaved CXCL12. The results showed a moderate, but significant, decrease in affinity 
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of cleaved CXCL12 to dermatan sulfate compared to intact CXCL12. However, there was no significant 
difference in affinity of both intact and cleaved CXCL12 to heparan sulfate, which is thought to be a 
major sink for extracellular CXCL12 (Janssens, et al., 2017). 
7.3. CXCL12 effect on bone marrow mesenchymal stem cells differentiation 
The role of CXCL12 in bone health is well established. CXCL12β was previously shown to potentiate the 
osteoinductive effect of bone morphogenetic protein 2. This effect was shown in vitro in genetically 
engineered bone marrow-derived mesenchymal stem cells (BMSCs), and in vivo in bone regeneration in 
critical-size rat calvarial defects (Herberg, et al., 2015; Herberg, et al., 2014). Our lab recently found that 
while intact CXCL12β(1-72) induces osteogenic differentiation in BMSCs, cleaved CXCL12β(3-72) inhibits 
osteogenic differentiation (Elmansi, et al., 2018) (Table 8). This result has major implications, as the 
balance between osteogenic and adipogenic differentiation in BMSCs is a crucial aspect in bone healing 
and healthy bone aging (Infante & Rodriguez, 2018). 
 
 
7.4. CXCL12 effect on cell migration: 
CXCR4 is required for CXCL12-mediated chemotaxis, and is a co-receptor for HIV cell binding and 
transfection. A paper by Shioda et al., in 1998 demonstrated that DPP4 abolished both chemotactic and 
anti-HIV-1 activities for CXCL12α and CXCL12β. Shioda et al., infected two different cell lines with a 
recombinant CXCL12α-expressing vector. The two cell lines were H9, a DPP4-expressing T-cell line, and 
MT4, a T-cell line that does not express DPP4. After 3 days, the results they found were intriguing; 
western blot analysis showed while there were similar total levels of CXCL12α in the supernatant of both 
cell lines, the chemotactic and anti-HIV-1 activities widely varied from remarkably high levels in non-
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DPP4 expressing MT4 cells to very low activity in DPP4 expressing H9 cells (Shioda, et al., 1998). 
Although this experiment did not directly test the biological activity of DPP4-cleaved CXCL12, it hints 
that there is an antagonistic action resulting from having DPP4 in close proximity to released CXCL12. 
Another experiment by Janssens et al., showed that DPP4-cleaved CXCL12α does not induce endothelial 
cell migration compared to intact CXCL12α. However, there was no control group to test the possibility 
that cleaved CXCL12α inhibits migration, instead of simply being inactive (Janssens, et al., 2017).  
Christopherson et al, reported that DPP4-cleaved CXCL12α(3-68) does not induced the migration of 
CD34+ HSCPs and even inhibits cellular migratory activity induced by intact CXCL12α (1-68). They 
suggested that DPP4 truncation of CXCL12α could represent a novel mechanism that regulates 
migration, mobilization, and homing of HSPCs (Christopherson, et al., 2003a; Christopherson, et al., 
2002; Christopherson, et al., 2004). Moreover, our lab recently found that pretreating BMSCs with 
cleaved CXCL12β(3-72) for 16 hours, diminishes their ability to migrate towards media containing intact 
CXCL12β(1-72) in transwell assays. This result is important in understanding stem cell migration and 
cancer cell metastasis. It also means that DPP4-cleaved CXCL12 is not simply inactive, but possesses a 
separate bioactivity that might be antagonistic to intact CXCL12 (Elmansi, et al., 2018) (Table 8) (Figure 
5). However, since DPP4 cleaved CXCL12 does not appear to effectively bind to CXCR4 based on 
competitive displacement of radiolabeled CXCL12 (1-68) by cold CXCL12 (3-68) [CXCL12(3-68)  kd = 464  
2nM compared to Kd = 1.44  1.5 nM for CXCL12(1-68) (Ziarek, et al., 2017) the reports of apparent 
antagonistic activity actually may be mediated by ACKR3 or alternative mechanisms via interactions with 
other receptors (Cheng, et al., 2017b; Janssens, et al., 2017). For example, ACKR3 activation may down-
regulate CXCR4 expression and therefore G-protein coupled signaling directly, or as a consequence of 
CXCR4/ACKR3 heterodimerization, which results in β-arrestin signaling while abrogating G-protein 
coupled signaling through CXCR4. Therefore, ACKR3 activation leads to decreased CXCR4 signaling and 
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inhibition of CXCR4 mediated migration and other actions (Decaillot, et al., 2011; Janssens, et al., 2018; 
Levoye, et al., 2009; Zabel, et al., 2009). 
7.5. CXCL12 effect on cell viability: 
We previously showed that intact CXCL12β mediates cell survival via upregulation of the autophagic 
pathway and inhibition of apoptosis in BMSCs (Herberg, et al., 2013a). However, another form of 
cleaved CXCL12(5-67) produced by the action of matrix metalloproteinase-2, was shown to induce NSC 
death through activating the intrinsic apoptotic pathway. This was evident by increased caspase 3/7 
activation in NSCs treated with cleaved CXCL12(5-67) compared to control. Intact CXCL12 on the other 
hand was shown to inhibit apoptosis and decrease caspase 3/7 activation in NSCs compared to control 
(Adelita, et al., 2017). 
7.6. CXCL12 effect on brain and nervous system: 
While there is no available data on DPP4-cleaved CXCL12(3-67) activity in the brain, studies showed that 
the previously-mentioned cleaved CXCL12 (5-67) is neurotoxic to human and mouse neurons with no 
chemotactic properties. It was also found that higher levels of CXCL12(5-67) in brain were associated 
with HIV-1 infection (McQuibban, et al., 2001; Zhang, et al., 2003). The interesting and relevant part, is 
that this form of cleaved CXCL12(5-67) did not act through CXCR4, the regular receptor for intact 
CXCL12, but exerted its neurotoxic and immunogenic actions through the chemokine receptor CXCR3, 
which also shares the ligand CXCL11 with ACKR3, which is promiscuous in being activation-prone by N-
terminal modified CXCL11 and CXCL12 (Benhadjeba, et al., 2018; Vergote, et al., 2006). This does not 
mean that DPP4-cleaved CXCL12 acts through CXCR3, but it reinforces the idea that a proteolytic 
enzyme can generate a new cryptic ligand to a receptor that was not activated by the intact parent 
peptide. 
7.7. CXCR4 and DPP4 Interactions: 
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Among the non-substrate proteins that bind CD26 are a number of receptors including the CXCL12 
receptor CXCR4 (Havre, et al., 2008). Binding of CXCL12- initiates the internalization of both CXCR4 and 
CD26 in the T-cell line, Jurkat J32, the B-cell line, SKW6.4, and peripheral blood lymphocytes , suggesting 
that these two proteins may function together and emphasizing the importance of understanding the 
actions of DPP4 cleaved ligands (Herrera, et al., 2001). 
7.8. CXCL12 Summary: 
CXCL12 is one of the most thoroughly studied cytokines in the literature. However, data regarding 
biological functions of DPP4-cleaved CXCL12 are just beginning to emerge. There have been a number of 
papers measuring DPP4-cleaved CXCL12(3-68) affinity, binding, and potential to activate CXCR4 or 
ACKR3 receptors (Cheng, et al., 2017b; Janssens, et al., 2017). It has been shown that DPP4-cleaved 
CXCL12(3-68) can bind and activate ACKR3 with reduced affinity, while it cannot activate CXCR4 at all , at 
least via GPCR signaling. There is however a suggestion that CXCL12(3-68) may signal via -Arrestin 2 
pathways for both ACKR3, and possibly CXCR4 (Cheng, et al., 2017b; Janssens, et al., 2017; Ziarek, et al., 
2017). In terms of binding to GAGs in extracellular matrix, cleaved CXCL12(3-68) binds a subset of GAGs 
with a slightly decreased affinity compared to intact CXCL12. The main biological function measured for 
cleaved CXCL12 in the literature has been its inability to provide the anti-HIV activity of the intact 
isoform (Crump, et al., 1997; Proost, et al., 1998). Our lab recently found that DPP4-cleaved CXCL12β(3-
72) has an antagonistic-like action to intact CXCL12β(1-72) in terms of BMSCs cell migration and 
osteogenic differentiation  (Elmansi, et al., 2018), while intact CXCL12β(1-72) induces BMSCs migration 
and osteogenic differentiation, cleaved CXCL12β(3-72) inhibits both of those CXCR4 G-protein mediated 
functions (Elmansi, et al., 2018). Again, this likely does not represent direct competitive inhibition of the 
intact isoform with the CXCR4 receptor, certainly not through the CXCR4 GPCR mechanism, and it is 
unclear if CXCL12(3-68) and CXCL12β(3-72) can bind effectively at physiological levels to CXCR4 (Cheng, 
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et al., 2017b; Crump, et al., 1997; Janssens, et al., 2017; Ziarek, et al., 2017). Further work needs to be 
done to assess other biological functions and potential mechanistic pathways through which DPP4-
cleaved CXCL12 is acting.  
 
Table 8: Effect of N-terminal cleavage on receptor activation and biological functions of CXCL12α and 
β 
 Intact CXCL12 Cleaved CXCL12 Ref. 
CXCR4 receptor  
     (G-protein agonist) 
High No activation 
(Cheng, et al., 2017b; 
Janssens, et al., 2017; 
Ziarek, et al., 2017) 
CXCR4 receptor  
     (β-arrestin recruitment) 
High 
(concentration 
biased) 
Very low with EC50 
>103  
(Cheng, et al., 2017b) 
ACKR3 receptor 
     (β-arrestin recruitment) 
High Decreased by 80-90% 
(Cheng, et al., 2017b; 
Janssens, et al., 2017) 
GAG binding High Slightly decreased (Janssens, et al., 2017) 
BMSCs osteogenic 
differentiation 
increases inhibits (Elmansi, et al., 2018) 
Cell migration chemotactic inhibits 
(Elmansi, et al., 2018; 
Janssens, et al., 2017; 
Shioda, et al., 1998) 
Anti-HIV-1 activity Present Absent (Shioda, et al., 1998) 
 
8. Conclusion: 
DPP4 proteolytic cleavage of different peptide hormones does not simply deactivate them. Rather, 
many studies have shown that DPP4 cleavage leads to changes in the intact ligand/substrate’s biological 
function mediated through alterations in the normal receptor(s) interactions or revealed cryptic 
interactions with receptors that do not recognize the intact ligand. Additionally, biological functions and 
receptor interactions usually attributed to the intact ligand may actually be due to the DPP4-cleaved 
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ligand. While this review focuses on the consequences of DPP4 enzymatic cleavage of five different 
substrates that belong to three different classes of biological molecules, it is important to mention that 
these constitute only a small number of DPP4 substrates. A large array of other proteins –including 
cytokines, modulatory factors, colony-stimulating factors, etc.- have been reported to be cleaved by 
DPP4 in different tissues and organs (Broxmeyer, et al., 2012; Christopherson, et al., 2003b; Ou, et al., 
2013).  
In the case of GLP-1, it was found that some of the actions attributed to intact GLP-1 can be attenuated 
or even completely blocked upon inhibition of DPP4 proteolytic activity. This, in addition to the 
previously mentioned findings, suggests that cleaved GLP-1 is itself responsible for some of the 
physiological actions that has been attributed to intact GLP-1. Blocking of GLP-1R reverses intact GLP-1 
activity, with no effect on cleaved GLP-1 activity. This observation indicates that cleaved GLP-1 is also 
acting through an unidentified receptor that is distinct from GLP-1R. This surprising conclusion about 
DPP4-cleaved ligands is paradigm shift that reveals a critical gap in our understanding and interpretation 
of research and clinical data related to vital signaling pathways. In the case of GLP-1 the clinical 
implications are significant, since it affects our understanding of insulin regulation in general and 
specifically through new implications of how anti-diabetic DPP4 inhibitors work. Further research in this 
area is essential, to better understand the potentially beneficial biological actions of cleaved GLP-1 that 
can be suppressed by the use of DPP4 inhibitors, as well as better understanding the physiology of 
extending the functional half-life of intact GLP-1. 
For GIP, DPP4 cleavage introduces a GIP receptor antagonistic feature that is strengthened by C-terminal 
cleavage by other proteolytic enzymes. While for the two neuropeptides PYY and NPY, DPP4 cleavage 
means the production of a more selective Y2 receptor agonist, instead of the non-selective intact form.  
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For CXCL12, it was found that DPP4 cleavage completely abolishes its ability to initiate CXCR4 GPCR 
activation, while it retains some of its ability to activate ACKR3, making it more selective to β-arrestin 
signal transduction pathways instead of GPCR pathways. Further, the ability of DPP4-cleaved CXCL12 to 
activate ACKR3 inhibiting CXCR4 signaling might explain DPP4-cleaved CXCL12’s apparent CXCR4 
antagonistic action in light of its apparent inability to bind effectively to CXCR4 (Ziarek, et al., 2017). 
Although this last point is needs further clarification. Importantly, there are hints that DPP4-cleaved 
CXCL12 may also act through alternative receptors and signaling pathways. This underscores the need to 
explore DPP4 cryptic ligands bioactivity not only for CXCL12, but more broadly among DPP4 substrates. 
In addition to the clinical significance these findings carry, they can also help us predict or understand 
how DPP4 and DPP4 inhibitors may affect cellular functions and biological processes of other important 
chemokines and polypeptides.  
Further, this review highlights the crucial need to standardize the collection and processing of samples 
to preserve the true in vivo molecular profiles. This is both in terms of the total quantities of specific 
molecules as well as the ratio or individual profiles of different proteolytic metabolites. Additionally, 
there is a critical need to develop new tools to measure these ligand isoforms for accurate quantitation 
and interpretation of experimental results. Importantly, we are also proposing that plasma, serum, 
urine, and other biological samples collected in clinical trials and for biorepositories need to have the 
samples protected at the point of collection from DPP4 and other proteolytic or enzymatic degradation 
to allow for not only accurate prospective analysis, but for retrospective use of these tissue banks and 
biorepositories. This has real world implications in understanding normal and pathological systems and 
quality of life and even life-or-death repercussions in the development of therapeutics for major 
diseases such as diabetes, osteoporosis, inflammation, stroke, myocardial infarction, wound repair and 
cancer. 
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Table 1: DPP4 intact substrates, and their amino acid sequences 
Substrate  Amino acid sequence Ref. 
GLP-1(7-
36) 
HA ↑ EGTFTSDVSSYLEGQAAKEFIAWLVKGR 
(Orskov, 
et al., 
1989) 
GIP(1-42) YA ↑ EGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ 
(Sparre-
Ulrich, et 
al., 2017) 
PYY(1-36) YP ↑ IKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY 
(Grandt, 
et al., 
1994a) 
NPY(1-36) YP ↑ SKPDNPGEDAPAEDMARYYSALRHYINLITRQRY 
(Tatemot
o, 1982) 
CXCL12α(
1-67) 
KP↑VSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQE
YLEKALNK 
(Dong, et 
al., 2012) 
↑ DPP4 proteolytic site 
 
 
 
 
 
 
 
Table 2: Biological functions of intact and cleaved GLP-1 alone and with exendin(9-39) (GLP-1R 
blocker) 
 Intact GLP-1(7-36) Cleaved GLP-1(9-36) Ref. 
Effect Alone With 
exendin(9-39) 
Alone With 
exendin(9-39) 
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Cell count Decrease No decrease Decrease Decrease (Cantini, et al., 
2017) 
Cell 
proliferation 
Decrease ND Decrease ND (Cantini, et al., 
2017) 
Apoptosis Increase ND Increase ND (Cantini, et al., 
2017) 
Adipogenesis Decrease No decrease Decrease Decrease (Cantini, et al., 2017; 
El Bekay, et al., 
2016) 
Glucose 
uptake 
Decrease ND Decrease ND (Cantini, et al., 
2017) 
Myocardial 
protective  
effects 
Increase Increase Increase Increase (Robinson, et al., 
2016; Sonne, et al., 
2008) 
ND: not determined 
 
 
 
 
 
 
Table 3: Receptor binding assays of intact and cleaved GLP-1 to GLP-1R 
 Intact GLP-1(7-36) Cleaved GLP-1(9-36) Ref. 
Saturation binding assay KD 1.29 ± 0.26 AU 0.214 ± 0.08 AU (Kuc, et al., 2014) 
Saturation binding assay BMAX 57.0 ± 14.5 AU 2.69 ± 0.74 AU (Kuc, et al., 2014) 
SPA binding assay Ki 0.102 nM 156 nM (Kuc, et al., 2014) 
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cAMP assay EC50 0.072 nM 7270 nM (Kuc, et al., 2014) 
cAMP assay EMAX 104% 8.93% (Kuc, et al., 2014) 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Effect of C-terminal and N-terminal cleavage on receptor binding and biological functions of 
GIP  
Effect GIP(1-42) GIP(3-42) GIP(1-30) GIP(3-30) Ref. 
GIP Receptor binding High Low High High (Hansen, et al., 2016) 
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Receptor activity Agonist 
Weak 
antagonist 
Agonist 
Strong 
antagonist 
(Hansen, et al., 2016) 
cAMP production Increase Decrease Increase Decrease (Kerr, et al., 2011) 
Insulin secretion Increase Decrease Increase Decrease 
(Kerr, et al., 2011; 
Sparre-Ulrich, et al., 
2017) 
 
 
 
 
 
 
 
 
 
 
Table 5: Receptor binding assays of GIP(1-30) and GIP(3-30) to GIP receptor 
 GIP(1-30) GIP(3-30) Ref. 
Competitive 
binding assay 
logIC50 
-9.05 ± 0.02 AU -8.63 ± 0.04 AU (Hansen, et al., 2016) 
Competitive 
binding assay Ki 
0.89 nM 2.3 nM  (Hansen, et al., 2016) 
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Table 6: Receptor selectivity and effect on food intake of intact and cleaved PYY 
 Intact PYY(1-36) Cleaved PYY(3-36) Ref. 
Receptor 
selectivity 
Y1, Y2, Y4, and Y5 
agonist 
Y2 agonist (Grandt, et al., 1994b) 
Food 
intake 
Decrease  
(no effect on DPP4-
deficient mice) 
Decrease  
(acts on DPP4-
deficient mice) 
(Batterham, et al., 2003; Chelikani, et al., 
2005; Moran, et al., 2005; Pittner, et al., 
2004; Tschop, et al., 2004) 
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Table 7: Receptor selectivity and effect on cell migration and food intake of intact and cleaved NPY 
 Intact NPY(1-36) Cleaved NPY(3-36) Ref. 
Receptor 
selectivity 
Y1, Y2, Y4, and Y5 agonist Y2 agonist 
(Grandt, et al., 
1996) 
Cell migration 
+  
(effect blocked with DPP4 
inhibition) 
+ 
(effect retained with DPP4 
inhibition) 
(Ghersi, et al., 2001) 
2 Hour food intake + ++ (Flynn, et al., 1998) 
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Table 8: Effect of N-terminal cleavage on receptor activation and biological functions of CXCL12α and 
β 
 Intact CXCL12 Cleaved CXCL12 Ref. 
CXCR4 receptor  
     (G-protein agonist) 
High No activation 
(Cheng, et al., 2017b; 
Janssens, et al., 2017; 
Ziarek, et al., 2017) 
CXCR4 receptor  
     (β-arrestin recruitment) 
High 
(concentration 
biased) 
Very low with EC50 
>103  
(Cheng, et al., 2017b) 
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ACKR3 receptor 
     (β-arrestin recruitment) 
High Decreased by 80-90% 
(Cheng, et al., 2017b; 
Janssens, et al., 2017) 
GAG binding High Slightly decreased (Janssens, et al., 2017) 
BMSCs osteogenic 
differentiation 
increases inhibits (Elmansi, et al., 2018) 
Cell migration chemotactic inhibits 
(Elmansi, et al., 2018; 
Janssens, et al., 2017; 
Shioda, et al., 1998) 
Anti-HIV-1 activity Present Absent (Shioda, et al., 1998) 
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